SiliconBeat

Map Pharmaceuticals of Mountain View said today it has suspended development of its drug candidate aimed at asthma in children after its development partner, AstraZeneca terminated its license agreement related to Unit Dose Budesonide. Earlier this year results from a Phase 3 clinical trial of the drug candidate failed to meet expectations in either Read the rest of this entry »

Map Pharmaceuticals, the Mountain View development stage pharmaceutical company, said today that the initial Phase 3 clinical trial for budesonide for the potential treatment of children with asthma did not meet expectations in either of the doses evaluated when compared with a placebo.

The study included Read the rest of this entry »